148 related articles for article (PubMed ID: 18199999)
1. Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study.
Berger GE; Wood SJ; Wellard RM; Proffitt TM; McConchie M; Amminger GP; Jackson GD; Velakoulis D; Pantelis C; McGorry PD
Neuropsychopharmacology; 2008 Sep; 33(10):2467-73. PubMed ID: 18199999
[TBL] [Abstract][Full Text] [Related]
2. Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial.
Berger GE; Proffitt TM; McConchie M; Yuen H; Wood SJ; Amminger GP; Brewer W; McGorry PD
J Clin Psychiatry; 2007 Dec; 68(12):1867-75. PubMed ID: 18162017
[TBL] [Abstract][Full Text] [Related]
3. Assessing Brain Metabolism With 7-T Proton Magnetic Resonance Spectroscopy in Patients With First-Episode Psychosis.
Wang AM; Pradhan S; Coughlin JM; Trivedi A; DuBois SL; Crawford JL; Sedlak TW; Nucifora FC; Nestadt G; Nucifora LG; Schretlen DJ; Sawa A; Barker PB
JAMA Psychiatry; 2019 Mar; 76(3):314-323. PubMed ID: 30624573
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective effects of ethyl-eicosapentaenoic acid in first episode psychosis: a longitudinal T2 relaxometry pilot study.
Wood SJ; Cocchi L; Proffitt TM; McConchie M; Jackson GD; Takahashi T; Pantelis C; McGorry PD; Berger GE
Psychiatry Res; 2010 May; 182(2):180-2. PubMed ID: 20413278
[TBL] [Abstract][Full Text] [Related]
5. Neurochemical effects of oxytocin in people at clinical high risk for psychosis.
Davies C; Rutigliano G; De Micheli A; Stone JM; Ramella-Cravaro V; Provenzani U; Cappucciati M; Scutt E; Paloyelis Y; Oliver D; Murguia S; Zelaya F; Allen P; Shergill S; Morrison P; Williams S; Taylor D; Lythgoe DJ; McGuire P; Fusar-Poli P
Eur Neuropsychopharmacol; 2019 May; 29(5):601-615. PubMed ID: 30928180
[TBL] [Abstract][Full Text] [Related]
6. Early treatment response in first episode psychosis: a 7-T magnetic resonance spectroscopic study of glutathione and glutamate.
Dempster K; Jeon P; MacKinley M; Williamson P; Théberge J; Palaniyappan L
Mol Psychiatry; 2020 Aug; 25(8):1640-1650. PubMed ID: 32205866
[TBL] [Abstract][Full Text] [Related]
7. Preliminary in vivo evidence of increased N-acetyl-aspartate following eicosapentanoic acid treatment in patients with bipolar disorder.
Frangou S; Lewis M; Wollard J; Simmons A
J Psychopharmacol; 2007 Jun; 21(4):435-9. PubMed ID: 16891338
[TBL] [Abstract][Full Text] [Related]
8. Impaired glutamine metabolism in NMDA receptor hypofunction induced by MK801.
Brenner E; Kondziella D; Håberg A; Sonnewald U
J Neurochem; 2005 Sep; 94(6):1594-603. PubMed ID: 16045441
[TBL] [Abstract][Full Text] [Related]
9. Medial temporal lobe glutathione concentration in first episode psychosis: a 1H-MRS investigation.
Wood SJ; Berger GE; Wellard RM; Proffitt TM; McConchie M; Berk M; McGorry PD; Pantelis C
Neurobiol Dis; 2009 Mar; 33(3):354-7. PubMed ID: 19118629
[TBL] [Abstract][Full Text] [Related]
10. N-Acetyl-Cysteine Supplementation Improves Functional Connectivity Within the Cingulate Cortex in Early Psychosis: A Pilot Study.
Mullier E; Roine T; Griffa A; Xin L; Baumann PS; Klauser P; Cleusix M; Jenni R; Alemàn-Gómez Y; Gruetter R; Conus P; Do KQ; Hagmann P
Int J Neuropsychopharmacol; 2019 Aug; 22(8):478-487. PubMed ID: 31283822
[TBL] [Abstract][Full Text] [Related]
11. Elevated Myo-Inositol, Choline, and Glutamate Levels in the Associative Striatum of Antipsychotic-Naive Patients With First-Episode Psychosis: A Proton Magnetic Resonance Spectroscopy Study With Implications for Glial Dysfunction.
Plitman E; de la Fuente-Sandoval C; Reyes-Madrigal F; Chavez S; Gómez-Cruz G; León-Ortiz P; Graff-Guerrero A
Schizophr Bull; 2016 Mar; 42(2):415-24. PubMed ID: 26320195
[TBL] [Abstract][Full Text] [Related]
12. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial.
Puri BK; Leavitt BR; Hayden MR; Ross CA; Rosenblatt A; Greenamyre JT; Hersch S; Vaddadi KS; Sword A; Horrobin DF; Manku M; Murck H
Neurology; 2005 Jul; 65(2):286-92. PubMed ID: 16043801
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal changes in brain metabolites in healthy controls and patients with first episode psychosis: a 7-Tesla MRS study.
Wang M; Barker PB; Cascella NG; Coughlin JM; Nestadt G; Nucifora FC; Sedlak TW; Kelly A; Younes L; Geman D; Palaniyappan L; Sawa A; Yang K
Mol Psychiatry; 2023 May; 28(5):2018-2029. PubMed ID: 36732587
[TBL] [Abstract][Full Text] [Related]
14. Nature of Glutamate Alterations in Schizophrenia: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies.
Merritt K; Egerton A; Kempton MJ; Taylor MJ; McGuire PK
JAMA Psychiatry; 2016 Jul; 73(7):665-74. PubMed ID: 27304221
[TBL] [Abstract][Full Text] [Related]
15. Altered medial temporal activation related to local glutamate levels in subjects with prodromal signs of psychosis.
Valli I; Stone J; Mechelli A; Bhattacharyya S; Raffin M; Allen P; Fusar-Poli P; Lythgoe D; O'Gorman R; Seal M; McGuire P
Biol Psychiatry; 2011 Jan; 69(1):97-9. PubMed ID: 21035785
[TBL] [Abstract][Full Text] [Related]
16. Effects of ethyl-eicosapentaenoic acid omega-3 fatty acid supplementation on hot flashes and quality of life among middle-aged women: a double-blind, placebo-controlled, randomized clinical trial.
Lucas M; Asselin G; Mérette C; Poulin MJ; Dodin S
Menopause; 2009; 16(2):357-66. PubMed ID: 19034052
[TBL] [Abstract][Full Text] [Related]
17. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia.
Fenton WS; Dickerson F; Boronow J; Hibbeln JR; Knable M
Am J Psychiatry; 2001 Dec; 158(12):2071-4. PubMed ID: 11729030
[TBL] [Abstract][Full Text] [Related]
18. Amino acid metabolic processes in the temporal lobes assessed by proton magnetic resonance spectroscopy (1H MRS) in children with Down syndrome.
Śmigielska-Kuzia J; Boćkowski L; Sobaniec W; Kułak W; Sendrowski K
Pharmacol Rep; 2010; 62(6):1070-7. PubMed ID: 21273664
[TBL] [Abstract][Full Text] [Related]
19. A 1H-MRS investigation of the medial temporal lobe in antipsychotic-naïve and early-treated first episode psychosis.
Wood SJ; Berger GE; Wellard RM; Proffitt T; McConchie M; Velakoulis D; McGorry PD; Pantelis C
Schizophr Res; 2008 Jul; 102(1-3):163-70. PubMed ID: 18456460
[TBL] [Abstract][Full Text] [Related]
20. Reduction in cerebral atrophy associated with ethyl-eicosapentaenoic acid treatment in patients with Huntington's disease.
Puri BK; Bydder GM; Manku MS; Clarke A; Waldman AD; Beckmann CF
J Int Med Res; 2008; 36(5):896-905. PubMed ID: 18831882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
